RFK Jr.'s Peptide Reclassification: What 14 Peptides Could Be Legalized for Compounding

In a development that has received far less attention than it deserves, HHS Secretary Robert F. Kennedy Jr. has mentioned that the FDA is considering reclassifying approximately 14 previously restricted peptides in a way that would once again permit lawful compounding pursuant to a prescription.

This is significant — and it's happening in parallel with the FDA's aggressive crackdown on GLP-1 compounding. The apparent contradiction reveals a more nuanced regulatory picture than the "FDA vs. compounders" narrative suggests.

What Peptides Are Likely Involved

While the specific list hasn't been formally published, the peptides most likely under consideration for reclassification include compounds that were placed on the FDA's "Difficult to Compound" list or removed from the 503B Bulks List in prior regulatory actions. Based on public statements and the upcoming PCAC meeting agenda, the candidates likely include:

BPC-157 (Body Protection Compound-157) — a synthetic peptide derived from a protein found in gastric juice, used in compounding for tissue repair, gut healing, and injury recovery. Among the most frequently compounded peptides prior to FDA restrictions.

Thymosin alpha-1 — an immune-modulating peptide used in compounding for immune support and chronic infection management. Has approved drug status in over 30 countries but not in the U.S.

Thymosin beta-4 — another thymic peptide used for wound healing and tissue repair. Commonly paired with BPC-157 in compounding protocols.

Additional candidates may include AOD 9604, CJC-1295, Ipamorelin, Sermorelin, PT-141, DSIP, Selank, Semax, and others that were commonly compounded before regulatory restrictions tightened.

The PCAC Meeting: July 23–24

The FDA's Pharmacy Compounding Advisory Committee (PCAC) has scheduled a meeting for July 23–24, 2026 that will directly address peptide compounding. This meeting will provide the clearest signal yet about which peptides the FDA may reclassify and under what conditions compounding would be permitted.

The PCAC's recommendations aren't binding — the FDA can accept, modify, or reject them. But historically, PCAC recommendations have strongly influenced final FDA policy on compounding matters.

What This Means for the GLP-1 Compounding Landscape

The peptide reclassification and the GLP-1 crackdown exist in the same regulatory environment but serve different policy goals. For GLP-1 medications, the FDA's concern is primarily about mass-market compounding that competes with FDA-approved products. For other peptides, there's no directly competing FDA-approved drug in most cases — which makes the clinical-need argument for compounding much stronger.

If the reclassification moves forward, it would signal that the current administration supports compounding pharmacy access in principle — just not for compounds that directly copy commercially available blockbuster drugs. That distinction matters for understanding where compounding regulation is heading in 2027 and beyond.